NACDS Foundation grant sponsors study on how pharmacogenomics can impact outcomes

ARLINGTON, Va. — The National Association of Chain Drug Stores Foundation on Thursday gave a $60,000 research grant to Manchester University Pharmacy Program to translate pharmacogenomics — the study of harnessing a patient’s genetic make-up to inform their treatment. Pharmacogenomics inform more than 360 million prescriptions annually — a number that’s expected to increase as the Food and Drug Administration and the pharmaceutical industry work to incorporate more pharmacogenomic testing in drug development.

                   

“Pharmacogenomics is the next frontier in patient care and patient safety with medication use,” NACDS Foundation President Kathleen Jaeger said. “Utilizing advanced technologies to harness genetic information can help identify the right treatments that are specific to the patient. The science of pharmacogenomics is rapidly evolving and can substantially influence patients’ medication regimens and ultimate health outcomes.”

 

Working in conjunction with pharmacogenomics research company RxGenomix, the Manchester University Pharmacy Program will use grant funds to develop and launch a pilot program to evaluate the impact of pharmacogenomics on pharmacy patient care. Specifically, the research project will provide pharmacogenomic services in community pharmacies including collection of DNA samples, interpretation of patient results, counseling and collaboration with prescribers to help optimize patient medication regimens. 

 

“Pharmacists clearly have a leading role to play in the appropriate application of pharmacogenomics in patient care,” David Kisor, professor and chair of Pharmaceutical Sciences at the Manchester University Pharmacy Program, said. “Education of pharmacists to best implement pharmacogenomics services and to educate other healthcare professionals and the public is critical. This study works toward that end.”